| PERIOD ENDING | 30-Jun-09 | 31-Mar-09 | | Total Revenue | 3 | 1 | | Cost of Revenue |
-
|
-
| | | Gross Profit | 3 | 1 | | | Operating Expenses | | Research Development |
-
|
-
| | Selling General and Administrative | 355 | 1,376 | | Non Recurring |
-
|
-
| | Others |
-
|
-
| | | | Total Operating Expenses |
-
|
-
| | | | Operating Income or Loss | (352) | (1,375) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | 10 | 15 | | Earnings Before Interest And Taxes | (342) | (1,360) | | Interest Expense | 0 | 0 | | Income Before Tax | (342) | (1,361) | | Income Tax Expense |
-
|
-
| | Minority Interest |
-
|
-
| | | | Net Income From Continuing Ops | (342) | (1,361) | | | Non-recurring Events | | Discontinued Operations |
-
|
-
| | Extraordinary Items |
-
|
-
| | Effect Of Accounting Changes |
-
|
-
| | Other Items |
-
|
-
| | | | Net Income | (342) | (1,361) | | Preferred Stock And Other Adjustments |
-
|
-
| | | Net Income Applicable To Common Shares | ($342) | ($1,361) |
|
0.11% Nasdaq 
0.01%
Income Statement
